Abstract
Use of Different Anti-PD-1 Checkpoint Combination Strategies for First-Line Advanced NSCLC Treatment—The Experience of Ion Chiricuță Oncology Institute
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have